Company

ImmunoPrecise Antibodies (IPA) is a full-service, therapeutic antibody discovery company offering species agnostic advancements such as the B cell Select™ single-cell interrogation technology, DeepDisplay™ custom phage libraries, as well as the Abthena™ bispecific program- platforms that blend seamlessly with IPA’s Artemis Intelligence Metadata (AIM)™ capabilities to enable rapid turnaround on additional algorithmic outputs in therapeutic optimization, stability, affinity and manufacturability.

IPA is focused on the next generation of antibody discovery, to deliver therapeutically relevant antibodies, in a short period of time, with high probability of succeeding to clinical trials. With over 30 years of experience in the custom antibody business, we have completed roughly 4000 projects for hundreds of clients across the globe, including a majority of the top 20 largest pharmaceutical companies.
Our discovery and development are conducted in Utrecht and Oss, the Netherlands (IPA Europe), and Victoria, British Columbia (IPA Canada) with headquarters located in Fargo, North Dakota. We operate multi-nationally to offer a continuum of antibody services, transforming the face of therapeutic discovery, by decreasing turnaround time and risk, and promoting clinical success.
We are comprised of experienced research and development scientists that encompass a wide range of distinctive competencies, including innovative technologies required in the production of monoclonal and polyclonal antibodies. We pride ourselves on our high customer satisfaction and our clients have grown accustomed to receiving very thorough and professional service. We customize your project to generate antibodies that meet your specific needs.

Management Team

Dr. Jennifer Bath

Chief Executive Officer and President

View Bio

Jennifer Bath is the CEO and President of ImmunoPrecise Antibodies. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry, with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.

Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. Here, she headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.

Lisa Helbling

Chief Financial Officer

View Bio

Lisa Helbling serves as the Chief Financial Officer for ImmunoPrecise Antibodies. At ImmunoPrecise, she oversees financial and strategic management, including the company’s financial reporting and long-range business planning. Additionally, she supervises human resources and legal. She brings over thirty years of broad experience in accounting, finance, enterprise risk management, audit, and ESOPs. Currently, she serves on the board of directors for Healthy Dakota Mutual Holdings and Blue Cross Blue Shield of North Dakota and is the Chair of the Audit & Compliance Committee. Prior to joining the executive team, Ms. Helbling served as CFO at Anchor Ingredients and TMI Hospitality, as well as VP of Internal Audit and Business Risk Management at Otter Tail Corporation.

Brad McConn

VP of Finance

View Bio

Brad McConn serves as the VP of Finance for ImmunoPrecise Antibodies. He is responsible for oversight of the company’s financial reporting, financial planning & analysis, and complex accounting research. Prior to his current role he served as the Director of Financial Planning & Analysis for ImmunoPrecise Antibodies, and previously worked as an analyst in the real estate industry, focusing on a broad range of financial processes and business development. He is a CFA® charterholder, and holds a Bachelor of Arts in Mathematics with Minors in Chemistry and Business.

Dr. Ilse Roodink

Chief Scientific Officer

View Bio

Dr. Ilse Roodink serves as Chief Scientific Officer (CSO) of ImmunoPrecise Antibodies, supporting the company’s global research and development teams. Prior to her appointment as CSO, she held different scientific positions at the Company’s Dutch facility in Oss from 2013 until 2021. In her last role as Scientific Director of ImmunoPrecise Europe, Dr. Roodink was overseeing contract research project execution and management and actively involved in the integration of innovative technologies supporting antibody characterization and engineering. Following its establishment in 2019, Dr. Roodink has served as Chairwoman of Talem Therapeutics’ Scientific Advisory Committee, leading the development of Talem’s pipeline assets.

Dr. Roodink graduated from Radboud University of Nijmegen, the Netherlands with a Master’s degree in Biomedical Health Sciences and a Ph.D. in Medical Sciences. Her work, resulting in several peer-reviewed publications, focused on platform development to facilitate the discovery of antibodies specifically recognizing native tumor targets.

Kari Graber

VP of Commercial Services

View Bio

Kari Graber serves as the Vice President of Commercial Services for ImmunoPrecise Antibodies, and is responsible for the overall leadership and implementation of the Project Management program throughout ImmunoPrecise’s global family of companies. She has over 20 years of experience in developing, implementing and directing laboratory operations, quality assurance, regulatory compliance, and supply chain management programs for various food manufacturers, and spent five years as Sales and Technical Director for a pasteurization/sterilization technology and equipment supplier. Prior to joining ImmunoPrecise, Ms. Graber served at Aldevron LLC, where she held a client relations management role for their antibody services platform. She holds a Bachelor of Science in Food Science & Technology and a Minor in Microbiology.

Carla Dahl

VP of Marketing

View Bio

Carla Dahl is an accomplished leader with more than 20 years of strategic brand and marketing experience in the bioscience and healthcare spaces. She has a proven track record of managing major marketing initiatives for medical device launches at both start-up and multi-national companies. Prior to joining ImmunoPrecise Antibodies as the VP of Marketing in 2021, she served as the VP of Marketing at Preceptis Medical, Sr. Director Global Marketing Communication and Marketing Operations at Medtronic, Director Global Marketing at St. Jude Medical, and Director of Marketing at Cardiovascular Systems. Ms. Dahl has a distinctive history of success managing the translation of complex medical and scientific concepts into smart, market-leading brands and omni-channel strategies.

Dr. Barry Duplantis

VP of Client Relations

View Bio

Dr. Barry Duplantis serves as Vice President of Client Relations for ImmunoPrecise Antibodies and is responsible for managing and coordinating all sales- related activities. He is a scientific entrepreneur and business development specialist with over 10 years experience in the commercial application of drug and vaccine discovery platforms. Prior to his appoint to VP of Client Relations he served as the Director of Client Relations for ImmunoPrecise Antibodies (Canada) and was the founder and CEO of DuVax Vaccine and Reagents. Dr. Duplantis obtained his Ph.D. from the Department of Microbiology and Biochemistry at the University of Victoria in 2012 with a focus on intracellular pathogenesis and vaccine development.

Dr. Debby Kruijsen

General Manager, ImmunoPrecise Antibodies Europe

View Bio

Dr. Debby Kruijsen is the General Manager of ImmunoPrecise Antibodies Europe, formerly ModiQuest Research (Oss, The Netherlands), which became part of the ImmunoPrecise family of companies in April 2018.

She began her career in immunology at Utrecht University in the Netherlands. In 2012, she joined ModiQuest Research where she held different scientific and management positions until she became General Manager of ImmunoPrecise Antibodies Europe. Dr. Kruijsen works closely with the executive and global teams to develop and execute business strategies, improve operational efficiencies, and support ImmunoPrecise as an innovative company in the CRO space.

Teri Otto

General Manager, ImmunoPrecise Antibodies Canada

View Bio

Teri Otto is the General Manager of ImmunoPrecise Antibodies Canada (Victoria, BC). She works closely with the executive and internal teams to implement best practices and company strategy. Ms. Otto has held a variety of scientific and management positions prior to her role as General Manager.

Ms. Otto holds a Bachelor of Science in Microbiology and Associate degrees in Psychology and Applied Chemistry/Biochemistry.

Dr. Jennifer Bath

Chief Executive Officer and President

View Bio

Jennifer Bath is the CEO and President of ImmunoPrecise Antibodies. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry, with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.

Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. Here, she headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.

Lisa Helbling

Chief Financial Officer

View Bio

Lisa Helbling serves as the Chief Financial Officer for ImmunoPrecise Antibodies. At ImmunoPrecise, she oversees financial and strategic management, including the company’s financial reporting and long-range business planning. Additionally, she supervises human resources and legal. She brings over thirty years of broad experience in accounting, finance, enterprise risk management, audit, and ESOPs. Currently, she serves on the board of directors for Healthy Dakota Mutual Holdings and Blue Cross Blue Shield of North Dakota and is the Chair of the Audit & Compliance Committee. Prior to joining the executive team, Ms. Helbling served as CFO at Anchor Ingredients and TMI Hospitality, as well as VP of Internal Audit and Business Risk Management at Otter Tail Corporation.

Brad McConn

VP of Finance

View Bio

Brad McConn serves as the VP of Finance for ImmunoPrecise Antibodies. He is responsible for oversight of the company’s financial reporting, financial planning & analysis, and complex accounting research. Prior to his current role he served as the Director of Financial Planning & Analysis for ImmunoPrecise Antibodies, and previously worked as an analyst in the real estate industry, focusing on a broad range of financial processes and business development. He is a CFA® charterholder, and holds a Bachelor of Arts in Mathematics with Minors in Chemistry and Business.

Dr. Ilse Roodink

Chief Scientific Officer

View Bio

Dr. Ilse Roodink serves as Chief Scientific Officer (CSO) of ImmunoPrecise Antibodies, supporting the company’s global research and development teams. Prior to her appointment as CSO, she held different scientific positions at the Company’s Dutch facility in Oss from 2013 until 2021. In her last role as Scientific Director of ImmunoPrecise Europe, Dr. Roodink was overseeing contract research project execution and management and actively involved in the integration of innovative technologies supporting antibody characterization and engineering. Following its establishment in 2019, Dr. Roodink has served as Chairwoman of Talem Therapeutics’ Scientific Advisory Committee, leading the development of Talem’s pipeline assets.

Dr. Roodink graduated from Radboud University of Nijmegen, the Netherlands with a Master’s degree in Biomedical Health Sciences and a Ph.D. in Medical Sciences. Her work, resulting in several peer-reviewed publications, focused on platform development to facilitate the discovery of antibodies specifically recognizing native tumor targets.

Kari Graber

VP of Commercial Services

View Bio

Kari Graber serves as the Vice President of Commercial Services for ImmunoPrecise Antibodies, and is responsible for the overall leadership and implementation of the Project Management program throughout ImmunoPrecise’s global family of companies. She has over 20 years of experience in developing, implementing and directing laboratory operations, quality assurance, regulatory compliance, and supply chain management programs for various food manufacturers, and spent five years as Sales and Technical Director for a pasteurization/sterilization technology and equipment supplier. Prior to joining ImmunoPrecise, Ms. Graber served at Aldevron LLC, where she held a client relations management role for their antibody services platform. She holds a Bachelor of Science in Food Science & Technology and a Minor in Microbiology.

Carla Dahl

VP of Marketing

View Bio

Carla Dahl is an accomplished leader with more than 20 years of strategic brand and marketing experience in the bioscience and healthcare spaces. She has a proven track record of managing major marketing initiatives for medical device launches at both start-up and multi-national companies. Prior to joining ImmunoPrecise Antibodies as the VP of Marketing in 2021, she served as the VP of Marketing at Preceptis Medical, Sr. Director Global Marketing Communication and Marketing Operations at Medtronic, Director Global Marketing at St. Jude Medical, and Director of Marketing at Cardiovascular Systems. Ms. Dahl has a distinctive history of success managing the translation of complex medical and scientific concepts into smart, market-leading brands and omni-channel strategies.

Dr. Barry Duplantis

VP of Client Relations

View Bio

Dr. Barry Duplantis serves as Vice President of Client Relations for ImmunoPrecise Antibodies and is responsible for managing and coordinating all sales- related activities. He is a scientific entrepreneur and business development specialist with over 10 years experience in the commercial application of drug and vaccine discovery platforms. Prior to his appoint to VP of Client Relations he served as the Director of Client Relations for ImmunoPrecise Antibodies (Canada) and was the founder and CEO of DuVax Vaccine and Reagents. Dr. Duplantis obtained his Ph.D. from the Department of Microbiology and Biochemistry at the University of Victoria in 2012 with a focus on intracellular pathogenesis and vaccine development.

Dr. Debby Kruijsen

General Manager, ImmunoPrecise Antibodies Europe

View Bio

Dr. Debby Kruijsen is the General Manager of ImmunoPrecise Antibodies Europe, formerly ModiQuest Research (Oss, The Netherlands), which became part of the ImmunoPrecise family of companies in April 2018.

She began her career in immunology at Utrecht University in the Netherlands. In 2012, she joined ModiQuest Research where she held different scientific and management positions until she became General Manager of ImmunoPrecise Antibodies Europe. Dr. Kruijsen works closely with the executive and global teams to develop and execute business strategies, improve operational efficiencies, and support ImmunoPrecise as an innovative company in the CRO space.

Teri Otto

General Manager, ImmunoPrecise Antibodies Canada

View Bio

Teri Otto is the General Manager of ImmunoPrecise Antibodies Canada (Victoria, BC). She works closely with the executive and internal teams to implement best practices and company strategy. Ms. Otto has held a variety of scientific and management positions prior to her role as General Manager.

Ms. Otto holds a Bachelor of Science in Microbiology and Associate degrees in Psychology and Applied Chemistry/Biochemistry.

Board of Directors

James Kuo, MD, MBA

Chairman and Director

Committee Served: Audit

View Bio

Dr. James (Jim) Kuo currently serves as Chief Executive Officer of Return Health and Managing Director of Athena Bioventures in La Jolla, CA. He is an experienced biotech industry executive and investor, who brings financial and management experience to the company. During his career, he has held executive positions in private as well as listed bioscience companies in the US, Canada, and Europe. He previously served as CEO of Tryp Therapeutics, Synthetic Biologics, BioMicro Systems, and Discovery Laboratories. Prior to that, Dr. Kuo was Associate Director in Corporate Licensing and Development at Pfizer and Managing Director of HealthCare Ventures, a $378 million venture fund. He received his MD from the University of Pennsylvania School of Medicine and his MBA from the Wharton School of Business. Dr. Kuo's undergraduate education is in molecular biology and music history from Haverford College.

Dr. Jennifer Bath

Director

View Bio

Dr. Jennifer Bath is the CEO and President of ImmunoPrecise Antibodies. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry, with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.

Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. Here, she headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.

Greg Smith

Director

Committees Served: Audit, Compensation

View Bio

Mr. Greg Smith is a seasoned capital markets veteran who held senior positions in investment banking and institutional fixed income portfolio management before transitioning to private equity with the acquisition of one of the largest HVAC companies in Western Canada. Mr. Smith held the position of Portfolio Manager for Phillips, Hagar & North & Executive Director, Canadian Securitization Group, CIBC World Markets in Toronto for close to ten years. Mr. Smith currently serves as President & Director of Broadway Refrigeration & Air Conditioning Co. Ltd. Mr. Smith earned an MBA from Dalhousie University, is a Chartered Financial Analyst and serves in advisory and board positions to multiple private and public ventures.

Dr. Anna. K. Pettersson

Director

Committee Served: Governance & Nominating

View Bio

Dr. Anna K. Pettersson, is an experienced leader and advisor with extensive expertise in life sciences strategy, business development, financial analysis, and pharmaceutical R&D. She is the owner and founder of Barnegat Advisors, LLC, which provides strategic advisory services to the life sciences industry. Throughout her career, Dr. Pettersson held a number of positions at Pfizer Inc., most recently in the role of Senior Director, Innovation Policy. Prior to that, she served as a senior member of a life sciences consulting team and directed business development for the Mount Sinai School of Medicine. Dr. Pettersson holds a B.S. in biology from the University of Uppsala, a Ph.D. in genetics and diabetology from the Karolinska Institute and was also a Postdoctoral Fellow at the Whitehead Institute for Biomedical Research and at Harvard Medical School.

Dr. Robert D. Burke

Director

Committees Served: Audit, Governance & Nominating

View Bio

Dr. Robert D. Burke is an Emeritus Professor at the University of Victoria, where he was a faculty member for over 35 years. He has a longstanding research interest in the molecular basis of cellular signaling in early embryonic development. His research involves production and characterization of antibodies and he employs them extensively with high-resolution optical imaging methods. Dr. Burke has published over 100 peer-reviewed publications and has supervised numerous trainees. He was Chair of the Department of Biochemistry and Microbiology for eight years, was on the University of Victoria Senate for twelve years, and served on numerous advisory and management committees nationally and internationally. Dr. Burke completed a BSc (Honours) and a PhD at the University of Alberta.

James Kuo, MD, MBA

Chairman and Director

Committee Served: Audit

Dr. James (Jim) Kuo currently serves as Chief Executive Officer of Return Health and Managing Director of Athena Bioventures in La Jolla, CA. He is an experienced biotech industry executive and investor, who brings financial and management experience to the company. During his career, he has held executive positions in private as well as listed bioscience companies in the US, Canada, and Europe. He previously served as CEO of Tryp Therapeutics, Synthetic Biologics, BioMicro Systems, and Discovery Laboratories. Prior to that, Dr. Kuo was Associate Director in Corporate Licensing and Development at Pfizer and Managing Director of HealthCare Ventures, a $378 million venture fund. He received his MD from the University of Pennsylvania School of Medicine and his MBA from the Wharton School of Business. Dr. Kuo's undergraduate education is in molecular biology and music history from Haverford College.

Dr. Jennifer Bath

Director

Dr. Jennifer Bath is the CEO and President of ImmunoPrecise Antibodies. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry, with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.

Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. Here, she headed the global client relations and high value target teams, and defined business strategies by applying knowledge based on the science, technology and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.

Greg Smith

Director

Committees Served: Audit, Compensation

Mr. Greg Smith is a seasoned capital markets veteran who held senior positions in investment banking and institutional fixed income portfolio management before transitioning to private equity with the acquisition of one of the largest HVAC companies in Western Canada. Mr. Smith held the position of Portfolio Manager for Phillips, Hagar & North & Executive Director, Canadian Securitization Group, CIBC World Markets in Toronto for close to ten years. Mr. Smith currently serves as President & Director of Broadway Refrigeration & Air Conditioning Co. Ltd. Mr. Smith earned an MBA from Dalhousie University, is a Chartered Financial Analyst and serves in advisory and board positions to multiple private and public ventures.

Dr. Anna K. Pettersson

Director

Committee Served: Governance & Nominating

Dr. Anna K. Pettersson, is an experienced leader and advisor with extensive expertise in life sciences strategy, business development, financial analysis, and pharmaceutical R&D. She is the owner and founder of Barnegat Advisors, LLC, which provides strategic advisory services to the life sciences industry. Throughout her career, Dr. Pettersson held a number of positions at Pfizer Inc., most recently in the role of Senior Director, Innovation Policy. Prior to that, she served as a senior member of a life sciences consulting team and directed business development for the Mount Sinai School of Medicine. Dr. Pettersson holds a B.S. in biology from the University of Uppsala, a Ph.D. in genetics and diabetology from the Karolinska Institute and was also a Postdoctoral Fellow at the Whitehead Institute for Biomedical Research and at Harvard Medical School.

Dr. Robert D. Burke

Director

Committees Served: Audit, Governance & Nominating

Dr. Robert D. Burke is an Emeritus Professor at the University of Victoria, where he was a faculty member for over 35 years. He has a longstanding research interest in the molecular basis of cellular signaling in early embryonic development. His research involves production and characterization of antibodies and he employs them extensively with high-resolution optical imaging methods. Dr. Burke has published over 100 peer-reviewed publications and has supervised numerous trainees. He was Chair of the Department of Biochemistry and Microbiology for eight years, was on the University of Victoria Senate for twelve years, and served on numerous advisory and management committees nationally and internationally. Dr. Burke completed a BSc and a PhD at the University of Alberta.

Your Privacy Matters

As part of ImmunoPrecise's shared values of Innovation, Collaboration, and Ownership, we take seriously the responsibility to protect our customer's intellectual property. Data drives every decision in the laboratory, ensuring its accurate and protected at every step is crucial in the success of our customer's projects. ImmunoPrecise has taken a defense-in-depth approach through industry-leading AI-enabled security technologies to protect intellectual property, and data from policy violations, intrusion, and breaches. Security and privacy concerns can be directed to: privacy@immunoprecise.com